Last reviewed · How we verify
Atropine 0.01%
Atropine blocks muscarinic acetylcholine receptors, preventing parasympathetic nervous system signaling.
Atropine blocks muscarinic acetylcholine receptors, preventing parasympathetic nervous system signaling. Used for Pupil dilation (mydriasis) for ophthalmic examination, Accommodation paralysis (cycloplegia) for refraction testing, Uveitis and anterior chamber inflammation.
At a glance
| Generic name | Atropine 0.01% |
|---|---|
| Also known as | Atropine gel, mucoadhesive atropine gel |
| Sponsor | University Hospital, Strasbourg, France |
| Drug class | Anticholinergic agent / Muscarinic antagonist |
| Target | Muscarinic acetylcholine receptors (M1-M5) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Atropine is an anticholinergic agent that competitively antagonizes muscarinic acetylcholine receptors throughout the body. By blocking these receptors, it inhibits parasympathetic effects such as pupil constriction, accommodation, salivation, and smooth muscle contraction. The 0.01% ophthalmic formulation is used to dilate the pupil and paralyze accommodation for diagnostic and therapeutic purposes.
Approved indications
- Pupil dilation (mydriasis) for ophthalmic examination
- Accommodation paralysis (cycloplegia) for refraction testing
- Uveitis and anterior chamber inflammation
Common side effects
- Blurred vision
- Photophobia
- Ocular irritation
- Systemic anticholinergic effects (if absorbed)
Key clinical trials
- Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
- Effects of Auricular Point Pressing With Pellets in Children With Insufficient Hyperopia Reserve (NA)
- The Effect and Safety of Different Doses of Atropine on Myopic Progression of Highly Myopic Children: Multi-centered Randomized Clinical Trial (NA)
- E7 TCR T Cells for Human Papillomavirus-Associated Cancers (PHASE1, PHASE2)
- The Effect of 0.01% Atropine Eye Drops on Axial Length and Refraction in Myopic Children Compared to a Control Group (PHASE2)
- PROTECT-Study: Prospective Research on Optimizing Atropine Concentration Escalation for Children's Myopia Prevention (PHASE1, PHASE2)
- Myopia Control Using Bright Light Therapy, Myopic Defocus and Atropine (NA)
- Combination Effect of Optical Defocus and Low Dose Atropine in Myopia Control (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atropine 0.01% CI brief — competitive landscape report
- Atropine 0.01% updates RSS · CI watch RSS
- University Hospital, Strasbourg, France portfolio CI